Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
Displaying: 71,203 trials in your specialties ()
View trials across your selected specialties

Vitamin E Supplementation in Burn Patients

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Burn Injury
View Full Trial
INTERVENTION

Drug: dl-alpha-tocopheryl acetate

Eligibility
  • Ages: 6 to 85 Months (Child)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Shriners Hospitals for Children, Galveston, Texas, United States

Brief Summary

Burned patients because of their increased oxidative stress have severely depleted vitamin E, which is a dietary antioxidant. Oxidative stress is responsible for much of the pathophysiology seen in burned patients, which leads to acute and chronic morbidity and mortality, in addition to a decrease in their quality of life. Oral vitamin E will be used to reverse the oxidative stress of burn injury and, in the process, decrease the secondary consequences of thermal trauma. This proposal will demonstrate the benefit of maintaining adequate vitamin E status.

Controlled Human Malaria Infection in Semi-Immune Kenyan Adults. (CHMI-SIKA)

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Malaria
View Full Trial
INTERVENTION

Biological: Plasmodium falciparum sporozoite (PfSPZ)

Eligibility
  • Ages: 18 to 45 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

KEMRI Wellcome Trust Research Programme, Kilifi, Coast, Kenya

Brief Summary

The investigators wish to understand how resistance to malaria develops and how this affects the growth rate of malaria in individuals who have past exposure to malaria.

Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Radiation of Neurocranial Region
View Full Trial
INTERVENTION

Radiation: Radiation according to indication with hippocampal sparing, Radiation: Radiation according to indication without hippocampal protection

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Universitätsklinikum Erlangen, Erlangen, Germany

Brief Summary

This randomized trial examines possible enhancements in live quality and neurocognitive functions in patients after radiotherapy of the neurocranial area with hippocampal sparing. Although the hippocampus has a crucial role in regard to neurocognition and memory, hippocampal region has been relatively disregarded in radiotherapy of neurocranium so far. Brain metastases in the hippocampal region are very rare and an infiltration of the hippocampus by meningioma or by pituitary adenoma just occurs when volume of the tumor is very high. This study aims to reduce the radiation dose in the hippocampal region to improve the quality of live and neurocognitive functions in patients without degrading prognosis or increasing probability of brain metastases in hippocampal region. Primary endpoint of the trial is quality of live and neurocognitive functions in patients after radiation of neurocranial region with hippocampal sparing compared with conventional radiotherapy of the neurocranial region without hippocampal sparing. Secondary endpoints are cerebral recurrence rate in hippocampal region and overall survival. It is planned to include a total number of 150 patients.

Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major

  • Status
    Recruiting
  • Phase
    Phase 4
  • Condition
    Thalassemia Major
View Full Trial
INTERVENTION

Drug: Busulfan, Drug: Cyclophosphamide, Drug: Fludarabine, Drug: Mycophenolate mofetil, Drug: Tacrolimus, Drug: Methotrexate, Drug: Thymoglobulin, Drug: Basiliximab

Eligibility
  • Ages: 2 to 18 Years (Child, Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

Brief Summary

The purpose of the study is to assess the safety and efficacy of haploidentical hematopoietic stem cell transplantation for patients with thalassemia major.

Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Carotid Artery Stenosis, Strokes
View Full Trial
INTERVENTION

Drug: Statin, Drug: Atorvastatin, Other: Placebo

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Valley Hospital, Ridgewood, New Jersey, United States

Brief Summary

The investigators hypothesize that pre-operative statin use is neuroprotective at maximal doses. The goals are to determine the safety, feasibility, and efficacy of maximizing statin doses for two weeks (12-18 days) prior to CEA using change in performance on a battery neuropsychometric tests as outcome measure. Study will recruit patients based on their preexisting statin regimen. The investigators hypothesize that in asymptomatic CEA patients: 1) Pre-operative statin use is neuroprotective against early cognitive dysfunction (eCD) and lowers the risk of early mortality. 2) Maximal doses may be essential in achieving optimal neuroprotection against eCD.

A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Dwarfism
View Full Trial
INTERVENTION

Drug: PEG-somatropin

Eligibility
  • Ages: 4 to 9 Years (Child)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Department of Pediatrics of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Wuhan, Hubei, China

Brief Summary

After the first stage (52 weeks) of Phase II clinical trial, Pegylated recombinant human growth hormone (PEG-rhGH) injection of appropriate dose in compliance with ISS clinical treatment strategy is used to treat children with ISS (Idiopathic Short Stature). The long-term efficacy and safety of the investigational product are evaluated, which can provide more scientific and reliable medication guidance information for clinical diagnosis and treatment.

Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT

  • Status
    Recruiting
  • Phase
    Phase 2 Phase 3
  • Condition
    Acute Myeloid Leukemia, Allogeneic Hematopoietic Stem Cell Transp...
View Full Trial
INTERVENTION

Drug: Decitabine plus Modified BUCY, Drug: Modified BUCY

Eligibility
  • Ages: 12 to 60 Years (Child, Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Brief Summary

The purpose of this prospective, open-label, randomized multicenter study is to evaluate the safety and efficacy of low dose decitabine in combination with modified BUCY vs modified BUCY as a myeloablative conditioning regimen for high-risk patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (Allo-HSCT).

Inflammatory Response In Schizophrenia

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Schizophrenia
View Full Trial
INTERVENTION

Drug: Natalizumab, Other: Placebo: normal saline

Eligibility
  • Ages: 18 to 50 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom

Brief Summary

Schizophrenia affects a significant proportion of the population and current levels of understanding of the illness is inadequate to treat it effectively. Converging lines of evidence suggest that neuroinflammation occurs in schizophrenia, and specifically over-activity of brain-resident immune cells called microglia. It is however unclear whether activated microglia play a primary role in schizophrenia, or whether this is a secondary phenomenon of no pathophysiological significance. The investigators therefore plan to test the effect of a monoclonal antibody (natalizumab) on psychotic symptoms in a cohort of first episode psychosis patients.

Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Colorectal Adenocarcinoma Metastatic to the Liver
View Full Trial
INTERVENTION

Drug: HAI, Drug: chemotherapy ± target therapy

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Zhongshan hosptial, Fudan University, Shanghai, China

Brief Summary

To date no prospective trials have been completed that demonstrated whether HAI is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in conversional resection rates and survival compared with chemotherapy (target therapy) alone. The primary objective of this trial is to determine conversional resection rates and survival for patients with colorectal cancer liver metastasis are treated with HAI plus chemotherapy ± target therapy, compared to chemotherapy ± target therapy only.

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM

  • Status
    Recruiting
  • Phase
    Phase 4
  • Condition
    Colorectal Cancer Liver Metastasis
View Full Trial
INTERVENTION

Device: Radiofrequency Ablation (RFA), Drug: chemotherapy ± target therapy

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Zhongshan hosptial, Fudan University, Shanghai, China

Brief Summary

To date no prospective trials have been completed that demonstrated whether RFA is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in overall survival compared with chemotherapy (target therapy) alone. The primary objective of this trial is to determine overall survival for patients with colorectal cancer liver metastasis are treated with radiofrequency ablation plus chemotherapy ± target therapy, compared to chemotherapy ± target therapy only.